SynthesisInternational ophthalmology2025
Efficacy of topical cyclosporine A in optimizing ocular surface and relieving dry eye symptoms after cataract surgery: a systematic review and meta-analysis of randomized controlled trials.
Synthesis in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeDry eye symptoms and signs are common following cataract surgery. Topical cyclosporine A (CsA) is an approved treatment of moderate-to-severe dry eye disease. However, its effectiveness in managing postoperative dry eye remains debated. This systematic review and meta-analysis aimed to evaluate the efficacy of topical CsA in managing dry eye symptoms and signs after cataract surgery.
methodsRandomized controlled trials (RCTs) assessing topical CsA in cataract surgery patients were identified through searches of PubMed, EMBASE, Web of Science, ClinicalTrials.gov, the Cochrane Library, and Google Scholar up to August 31, 2024. Outcomes included postoperative tear break-up time (TBUT), Schirmer's test (with or without anesthesia), the Ocular Surface Disease Index (OSDI), corneal fluorescein staining, and treatment-related adverse events.
resultsNine RCTs involving 451 patients (558 eyes) were included. Topical CsA was significantly associated with prolonged TBUT (mean difference [MD] = 1.95 s, 95% confidence interval [CI]: 1.38 to 2.53, P < 0.001), improved Schirmer's test scores without anesthesia (MD = 2.14 mm, 95%CI: 0.68 to 3.59, P = 0.004), and reduced corneal fluorescein staining (standardized MD = - 1.62, 95%CI: - 3.16 to - 0.08, P = 0.039). However, CsA did not significantly improve Schirmer's test scores with anesthesia (MD = 1.73 mm, 95%CI: - 0.11 to 3.56 to 2.79, P = 0.066) or OSDI scores (MD = - 2.73, 95%CI: - 7.42 to 1.97, P = 0.255) compared to control. All treatment-related adverse events were mild.
conclusionTopical CsA significantly improves ocular surface and tear film parameters following cataract surgery and may be considered for the postoperative management of ocular surface disturbance and dry eye. However, considering the very low to moderate certainty of evidence, further high-quality RCTs are needed to validate for these findings.
Indexed as
Identifiers
40381053What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.